Gold-Palladium Nanoparticles for Treating Triple-Negative Breast Cancer
Author Information
Author(s): Gharibkandi Nasrin Abbasi, Majkowska-Pilip Agnieszka, Walczak Rafał, Wierzbicki Mateusz, Bilewicz Aleksander
Primary Institution: Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Warsaw, Poland
Hypothesis
Can Au@109Pd core-shell nanoparticles conjugated to panitumumab effectively target and treat triple-negative breast cancer?
Conclusion
Au@109Pd-PEG-panitumumab nanoparticles show potential as a therapeutic agent for targeted radionuclide therapy of triple-negative breast cancer.
Supporting Evidence
- Triple-negative breast cancer is highly invasive and lacks effective treatment options.
- EGFR expression is present in triple-negative breast cancer, making it a target for therapies.
- Au@109Pd nanoparticles can deliver radiation directly to cancer cells, enhancing treatment efficacy.
Takeaway
Scientists created tiny gold and palladium particles that can help treat a tough type of breast cancer by delivering radiation directly to the cancer cells.
Methodology
The study involved synthesizing Au@109Pd nanoparticles, conjugating them with panitumumab, and testing their effectiveness in targeting and reducing the metabolic activity of MDA-MB-231 breast cancer cells.
Limitations
The study suggests that systemic administration of the nanoparticles may not be feasible due to potential accumulation in non-target organs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website